Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Presentations
Sponsored
Interactive Tools
Learning Modules
Presentations
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia - Episode 1
Risk Assessment in Newly Diagnosed CLL
December 24, 2019
Now Viewing
EP. 1: Risk Assessment in Newly Diagnosed CLL
EP. 2: Up-front Ibrutinib Versus FCR for Patients With CLL
EP. 3: Frontline Antibodies With BTK Inhibitors for CLL
EP. 4: Toxicities With BTK Inhibitors for CLL
EP. 5: Comparison of BTK Inhibitors for CLL
EP. 6: Obinutuzumab + Venetoclax for Frontline CLL
EP. 7: MRD Testing for CLL
EP. 8: Ibrutinib + Venetoclax for Frontline CLL
EP. 9: Resistance Mechanisms Associated With BTK Inhibitors
EP. 10: Progression on Frontline Ibrutinib in CLL
EP. 11: Venetoclax in R/R CLL
EP. 12: BTK Inhibitors in R/R CLL
EP. 13: PI3K Inhibitors in R/R CLL
EP. 14: Novel Combinations in Development for CLL
EP. 15: Final Thoughts From ASH 2019 in CLL
Related Content:
A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Hematologic Oncology
Oncology Nursing News
Supportive Care
Dr Dorritie on Acalabrutinib With/Without Obinutuzumab in Treatment-Naive CLL
Dr Danilov on the Current and Potential Use of Pirtobrutinib in CLL
Zanubrutinib Associated With Lower Switching Rates vs Other Covalent BTK Inhibitors in CLL/SLL